CapsoVision, Inc. (CV), a medical technology firm, has successfully closed a $14 million private placement, selling 2.87 million shares at $4.883 each. This funding will support its ongoing development of advanced imaging and AI-enabled capsule endoscopy solutions for gastrointestinal diseases, including its flagship product, CapsoCam Plus, which recently received FDA approval for pediatric use.
The company reported preliminary revenues of $3.9 million for Q4 2025 and expects full-year revenues of $13.6 million, marking a significant step for a company that only went public in July 2025. With cash and investments totaling approximately $10.1 million as of year-end 2025, CapsoVision is positioned for growth in the burgeoning medical imaging sector.
For investors, the recent stock performance is noteworthy; CV shares closed at $6.87, up 11.17%, reflecting market optimism around its innovative offerings and strategic funding. The upcoming detailed financial results on March 26, 2026, will be crucial for assessing future growth potential.
Source: nasdaq.com